Simplest explanation (although I admit it makes little
Simplest explanation (although I admit it makes little sense) is flippers are continuing to enter at 16 (lower BB) in spite of the stock being completely illiquid. The stock is practically impossible to flip at the moment. All volume is being funneled down and even so there is very little sell volume.
Even the MM haven't been applying any downward pressure.
It kind of looks like 10-15 million shares are constantly cycling between flippers.
Like clockwork, resistance is being constantly provided to prevent the stock from breaking 19/20. (10MA (19), 20MA (18), and now the 50MA (19))
It's retail with 2 million at 18.
GLTA
CYduct Diagnostics Inc. (CYDX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Top 5 Most Recently Viewed Articles
Introduction to Q1 Investor Conferences This year has begun with a dynamic mix of geopolitical events that have positively impacted domestic energy-sector stocks. As we venture into 2026, the buzz around technological advancements, especially in artificial intelligence, is palpable. Investors are keenly awaiting insights and trends that will be presented at various...
Continue Reading
Overview of the November 2024 Podcast Metrics Triton Digital, a leading provider of technology and services in the digital audio and podcasting sector, has unveiled its reporting period for November 2024, covering from November 4 to December 1. This release comes from Triton’s Podcast Metrics measurement service, which offers critical insights into podcast performances...
Continue Reading
Overview of Treasury Bonds Auction Results In a recent auction, two significant treasury bonds were featured: RIKB 26 1015 and RIKB 38 0215. The auction process is a crucial activity in the finance world, presenting opportunities for investors to acquire bonds issued by the government. Each bond serves different funding needs, making it essential to assess their...
Continue Reading
DeepQure Welcomes New Global Vice President DeepQure, a trailblazer in innovative treatments for hypertension, has made a significant step forward with the recent appointment of Jason G. Jones as the Global Vice President of Clinical & Regulatory Affairs. This strategic move is expected to amplify DeepQure's ambitions as it seeks to redefine hypertension management with...
Continue Reading
Wave Life Sciences Presents Preclinical Findings at ObesityWeek 2025 Wave Life Sciences Ltd. (NASDAQ: WVE), a pioneering biotechnology firm, is excited to share breakthrough preclinical data on WVE-007, an innovative siRNA therapeutic targeting obesity. This research will be spotlighted in a poster presentation at ObesityWeek 2025, which features insights into how WVE-007...
Continue Reading